3-Hydroxy-3-methylglutaryl-CoA reductase (HMGCR) is the target of the statins, important
drugs that lower blood cholesterol levels and treat cardiovascular disease. Consequently,
the regulation of HMGCR has been investigated in detail. However, this enzyme acts very
early in the cholesterol synthesis pathway, with∼ 20 subsequent enzymes needed to
produce cholesterol. How they are regulated is largely unexplored territory, but there is
growing evidence that enzymes beyond HMGCR serve as flux-controlling points. Here, we …